Treatment of Angiotensin Peptide (1-7) for COVID-19
Treatment of Angiotensin Peptide (1-7) for COVID-19
Novel Coronavirus is reported to cause COVID-19, recently. It's known that this virus uses
 ACE (angiotensin converting enzyme) 2 receptors to enter human cells and also blocks the
 activity of ACE 2. Upon these data the investigators hypothesize that, mortal
 hyper-inflammation state which is shown in COVID-19 cases, can be a result of angiotensin
 peptide (1-7) deficiency. Therefore, the aim of this study is to evaluate the possible effect
 of angiotensin peptide (1-7) supplementation on treatment of COVID-19 cases.
Novel Coronavirus is reported to cause COVID-19, recently. It's known that this virus uses
 ACE (angiotensin converting enzyme) 2 receptors to enter human cells and also blocks the
 activity of ACE 2. Upon these data the investigators hypothesize that, mortal
 hyper-inflammation state which is shown in COVID-19 cases, can be a result of angiotensin
 peptide (1-7) deficiency. Therefore, the aim of this study is to evaluate the possible effect
 of plasma derived angiotensin peptide (1-7) supplementation on treatment of COVID-19 cases.
Inclusion Criteria:

 -  accepted to participate with an informed consent

 -  proven positive COVID-19

 Exclusion Criteria:

 -  declined to participate

 -  genetic/chromosomal abnormalities

 -  any kind of history of previous adverse events with transfusion

 -  diagnosis of immune deficiency